Edition:
United Kingdom

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

11.50USD
8:59pm GMT
Change (% chg)

$-0.32 (-2.71%)
Prev Close
$11.82
Open
$11.82
Day's High
$12.25
Day's Low
$11.42
Volume
102,275
Avg. Vol
79,605
52-wk High
$12.25
52-wk Low
$2.52

Select another date:

Wed, Jan 3 2018

BRIEF-Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals

* ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017 Source text: (http://bit.ly/2Ac7p5t) Further company coverage:

BRIEF-RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals

* RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING

BRIEF-Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals

* BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING

BRIEF-Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock

* DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK

BRIEF-Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering

* DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING Source text : (http://bit.ly/2o22t2b) Further company coverage:

BRIEF-Dicerna announces proposed public offering of common stock

* DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS Source text for Eikon: Further company coverage:

BRIEF-Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC

* DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA

BRIEF-Dicerna Pharmaceuticals Q3 loss per share ‍$0.92

* Q3 2017 loss per share ‍$0.92 Source text for Eikon: Further company coverage:

BRIEF-Boehringer, Dicerna collaborate to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis

* Boehringer Ingelheim and Dicerna announce collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis (NASH)

BRIEF-Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria

* Dicerna files clinical trial application for DCR-PHXC, the company’s most advanced GalXC™ product candidate, for phase 1 study in primary hyperoxaluria (ph)

Select another date: